These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30883315)

  • 1. Show Us (the U.S.) the Savings.
    Reinke T
    Manag Care; 2019 Jan; 28(1):9-10. PubMed ID: 30883315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.
    Beinfeld MT; LaMountain F; Wong W; Kim E; Chambers JD
    Health Aff (Millwood); 2024 Sep; 43(9):1290-1295. PubMed ID: 39226499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bringing Humira (Its Price) Down a Peg.
    Ladika S
    Manag Care; 2019 Jan; 28(1):7-8. PubMed ID: 30883314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
    Grewal S; Ramsey S; Balu S; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
    van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
    BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
    Williamson R; Munro T; Ascher D; Robertson A; Pregelj L
    Value Health; 2024 Mar; 27(3):287-293. PubMed ID: 38141814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White paper: an outlook on U.S. biosimilar competition.
    Bourgoin AF; Nuskey B
    Drugs Today (Barc); 2013 Jun; 49(6):399-410. PubMed ID: 23807943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: a cure to the U.S. health care cost conundrum?
    Hirsch BR; Lyman GH
    Blood Rev; 2014 Nov; 28(6):263-8. PubMed ID: 25260225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.